Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes
نویسندگان
چکیده
AIMS/INTRODUCTION Early initiation of basal insulin therapy is recommended for normalizing fasting blood glucose in type 2 diabetes mellitus. However, basal insulin treatment might not adequately control postprandial glucose levels. The present study evaluated whether the combination of the α-glucosidase inhibitor, acarbose, and basal insulin improved blood glucose control under daily-life treatment conditions in a large sample of Korean patients. MATERIALS AND METHODS The present study was a multicenter, prospective, observational study under daily-life treatment conditions. A total of 539 patients with type 2 diabetes who were treated with basal insulin and additional acarbose were enrolled and followed up for 20 weeks. Changes in hemoglobin A1c, fasting and postprandial blood glucose were evaluated at baseline and at the end of the observation period. The physician and patient satisfaction of the combination treatment and safety were assessed. RESULTS Hemoglobin A1c decreased by 0.55 ± 1.05% from baseline (P < 0.0001). Fasting and postprandial blood glucose levels were reduced by 0.89 ± 3.79 and 2.59 ± 4.77 mmol/L (both P < 0.0001). The most frequently reported adverse drug reactions were flatulence (0.37%) and abnormal gastrointestinal sounds (0.37%), and all were mild in intensity and transient. In the satisfaction evaluation, 79.0% of physicians and 77.3% of patients were 'very satisfied' or 'satisfied' with the combined basal insulin and acarbose therapy. CONCLUSIONS Combination therapy of basal insulin and acarbose in patients with type 2 diabetes improved glucose control, and had no drug-specific safety concerns, suggesting that the treatment might benefit individuals who cannot control blood glucose with basal insulin alone.
منابع مشابه
اثر درمان سه دارویی خوراکی در کنترل قند و لیپید بیماران مبتلا به دیابت تیپ 2
Background and Objective: Although patients with uncontrolled type 2 Diabetes mellitus(DM) despite conventional treatment with oral hypoglycemic agents eventually require insulin to achieve glycemic control, most of them reject use of insulin. To evaluate the efficacy of adding acarbose to full doses of conventional oral hypoglycemic agents on the metabolic control of the patients this study wa...
متن کاملSubject Index Volume 6
acarbose combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes, Kim 219–226 add-on therapy efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus, Seino 443–453 adenosine triphosphate-sensitive K+ channel fructose induces glucose-dependent insulinotro...
متن کاملAcarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients.
BACKGROUND Acarbose is an oral antidiabetic mainly acting on postprandial blood glucose, inhibiting alphaglucosidase. Through this mechanism, it could improve the peripheral insulin sensitivity and/or increase the insulin secretion. The aim of the present study is to assess the therapeutic efficacy of Acarbose in obese type 2 diabetic patients on both insulin resistance and insulin secretion. ...
متن کاملPostprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study
BACKGROUND Postprandial hyperglycemia is believed to affect vascular endothelial function. The aim of our study was to compare the effects of acarbose and nateglinide on postprandial endothelial dysfunction. METHODS We recruited a total of 30 patients with newly diagnosed type 2 diabetes (19 men and 11 women, age 67.8 +/- 7.3 years). Patients were randomly assigned to 3 groups receiving eithe...
متن کاملTreating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
OBJECTIVE Postprandial hyperglycemia characterizes early type 2 diabetes. We investigated whether ameliorating postprandial hyperglycemia with acarbose would prevent or delay progression of diabetes, defined as progression to frank fasting hyperglycemia, in subjects with early diabetes (fasting plasma glucose [FPG] <140 mg/dl and 2-h plasma glucose > or =200 mg/dl). RESEARCH DESIGN AND METHOD...
متن کامل